Faculty of Pharmacy and Pharmaceutical Sciences, 3133 Dentistry/Pharmacy Centre, University of Alberta, Edmonton, Alberta, Canada.
Adv Drug Deliv Rev. 2011 Sep 10;63(10-11):943-55. doi: 10.1016/j.addr.2011.05.021. Epub 2011 Jun 6.
Development of safe and effective cancer vaccine formulation is a primary focus in the field of cancer immunotherapy. The recognition of the crucial role of dendritic cells (DCs) in initiating anti-tumor immunity has led to the development of several strategies that target vaccine antigens to DCs as an attempt for developing potent, specific and lasting anti-tumor T cell responses. The main objective of this review is to provide an overview on the application of poly (d,l-lactic-co-glycolic acid) nanoparticles (PLGA-NPs) as cancer vaccine delivery system and highlight their potential in the development of future therapeutic cancer vaccines. PLGA-NPs containing antigens along with immunostimulatory molecules (adjuvants) can not only target antigen actively to DCs, but also provide immune activation and rescue impaired DCs from tumor-induced immuosupression.
开发安全有效的癌症疫苗制剂是癌症免疫治疗领域的主要重点。树突状细胞（DCs）在启动抗肿瘤免疫中的关键作用的认识，促使人们开发了几种将疫苗抗原靶向 DCs 的策略，以期产生强大、特异和持久的抗肿瘤 T 细胞反应。本综述的主要目的是概述聚（丙交酯-乙交酯）纳米粒（PLGA-NPs）作为癌症疫苗传递系统的应用，并强调其在未来治疗性癌症疫苗开发中的潜力。载有抗原和免疫刺激分子（佐剂）的 PLGA-NPs 不仅可以主动将抗原靶向 DCs，还可以提供免疫激活，并从肿瘤诱导的免疫抑制中拯救受损的 DCs。
